TATA健康发布2024年中期业绩 股东应占亏损513万港元 同比收窄58.38%

Core Viewpoint - TATA Health (01255) reported a revenue of HKD 72.309 million for the six months ending June 30, 2024, representing a year-on-year decrease of 30.56% [1] - The loss attributable to the company's owners narrowed to HKD 5.13 million, a reduction of 58.38% compared to the previous year [1] - The basic loss per share was HKD 0.02 [1] Financial Performance - Revenue for the period was HKD 72.309 million, down 30.56% year-on-year [1] - Loss attributable to owners was HKD 5.13 million, which is a 58.38% improvement from the prior year [1] - Basic loss per share recorded at HKD 0.02 [1]